Showing 3511-3520 of 4164 results for "".
- Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisorhttps://modernod.com/news/opthea-appoints-arshad-m-khanani-md-ma-fasrs-as-chief-medical-advisor/2482120/Opthea announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani is a managing partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates, and Clinic
- Oxurion to File for Bankruptcy After Failed DME Trialhttps://modernod.com/news/oxurion-to-file-for-bankruptcy-after-failed-dme-trial/2481978/Oxurion said it has decided to file for bankruptcy after announcing topline data from its KALAHARI phase 2, Part B trial for diabetic macular edema (DME). The trial did not demonstrate that its novel PKal inhibitor, THR-149, improved vision as much as the comparator,
- Graybug Updates its Ophthalmic Pipeline Programshttps://modernod.com/news/graybug-updates-its-ophthalmic-pipeline-programs/2480733/Graybug Vision announced a strategic update on its pipeline programs GB-102 in wet age-related macular degeneration (AMD); GB-401, in primary open-angle glaucoma (POAG); as well as its newly acquired assets in corneal disease (GB-501); inherited retinal diseases (GB-601); and
- Blue Light Glasses: Helpful or Just Hype?https://modernod.com/news/blue-light-glasses-helpful-or-just-hype/2477179/Erin Lynn Sattler started worrying when her vision became blurry while using the computer, but her eye doctor said her eyes were fine. Then she got a new computer at work, with a much brighter screen, and her eyes and head started hurting. She’d heard of blue light glasses and did some
- Lineage's RG6501 (OpRegen) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Meetinghttps://modernod.com/news/lineages-rg6501-opregen-phase-12a-results-will-be-featured-at-2024-angiogenesis-meeting/2482068/Lineage Cell Therapeutics announced that results showing retinal structure improvements with RG6501 (OpRegen) from a phase 1/2a clinical study (ClinicalTrials.gov Identifier:
- PulseMedica Raises $12 Million to Advance Eye Floater Imaging and Treatment Technologyhttps://modernod.com/news/pulsemedica-raises-12-million-to-advance-eye-floater-imaging-and-treatment-technology/2482360/PulseMedica announced that it has raised an aggregate of $12 million to date in investment as part of their pre-Series A financing round. This investment allowed PulseMedica to generate initial results from their preclinical and clinical studies, and will continue to accelerate the clinical valid
- Clearside Biomedical Announces Data Presentations at the AAO 2020https://modernod.com/news/clearside-biomedical-announces-data-presentations-at-the-aao-2020/2478556/Clearside Biomedical announced that two presentations of Clearside preclinical and clinical data were given at the virtual American Academy Ophthalmology (AAO) 2020 Annual Meeting. Clearside also announced a clinical characterization of the suprachoroidal in
- Revenio Group to Acquire Visionix in 290 Million Euro Dealhttps://modernod.com/news/revenio-group-to-acquire-visionix-in-290-million-euro-deal/2486649/Revenio Group has signed an agreement to acquire the entire share capital of France-based LT International SAS, the parent company of the Visionix International group, in a transaction valued at €290 million ($342 million). T
- VisionHQ Establishes Advisory Boardhttps://modernod.com/news/visionhq-establishes-advisory-board/2486441/VisionHQ, which provides in-house membership management and loyalty platform for eye care providers, has announced the formation of its Advisory Board. The move marks a strategic step forward in the company’s mission to help optometry practices boost patient retenti
- Contact Lens Institute Names 17 Eye Care Leaders as 2026 Visionarieshttps://modernod.com/news/contact-lens-institute-names-17-eye-care-leaders-as-2026-visionaries/2485504/Key Takeaways Contact Lens Institute named 17 U.S. and Canadian eye care professionals as 2026 Visionaries